Vascular endothelial growth factor as a marker of endothelial dysfunction in poly- and comorbidity: focus on hypertension, type 2 diabetes mellitus and subclinical hypothyroidism
Abstract
Background. The goal of our study was to investigate the content and particularities of change of vascular endothelial
growth factor-A (VEGF-A) levels as a marker of endothelial dysfunction (ED) in patients with hypertension
(HT) with or without type 2 diabetes mellitus (T2DM) and with or without subclinical hypothyroidism (SH).
Material and methods. Two hundred and eleven patients with hypertension stage II were divided into 3 groups:
Group 1 — with HT (n = 55); Group 2 — with AH and T2DM (n = 97); Group 3 — with HT, T2DM and SH
(n = 59). The patients in Group 3 were divided into 3 subgroups depending on TSH levels: 3a (n = 26) — TSH
4.0–6.0 mIU/L; 3b (n = 20) — TSH 6.1–8.0 mIU/L; 3c (n = 13) — TSH 8.1–10.0 mIU/L. We evaluated lipids,
carbohydrate metabolism, serum insulin concentration, insulin resistance index — HOMA, and the level of
VEGF-A in plasma.
Results. The levels of VEGF-A in Group 2 was significantly lower vs. Group1 (323.94 ± 22.17 pg/mL
and 413.15 ± 29.02 pg/mL, respectively (p < 0.05)). The patients in Group 3d had lower VEGF-A levels than
the patients in Group 1, but higher than those in Group 2. Among Group 3 patients, the levels of VEGF-A
were the lowest in the 3a subgroup (375.91 ± 19.81 pg/mL), significantly different from 3b and 3c subgroups
(p < 0.05), for which no differences were found (p > 0.05.). In the 3a subgroup VEGF-A levels were significantly
higher than in Group 2 patients (p < 0.05).
Conclusion. These data confirms the hypothesis of increasing ED in hypothyroidism even at the subclinical level.
Keywords: arterial hypertensiontype 2 diabetes mellitussubclinical hypothyroidismendothelial dysfunctionvascular endothelial growth factor
References
- Kuryata OV, Grechanyk MM. [Functional condition of vascular endothelium in patients with coronary heart disease in combination with non-alcoholic fatty liver disease, depending on weight and influence of statin therapy]. Zaporozhye Med J. 2015(1).
- Makurina GI. [Study of the vascular endothelium mechanisms activation in patients with psoriasis and arterial hypertension]. Zaporozhye Med J. 2016(94): 19–24.
- Smirnova E.N., Shulkina S.G., Schekotov V.V., Antipova A.A. [Vascular endothelial growth factor as a marker of endothelial dysfunction and early kidney damage in patients with metabolic syndrome]. Modern problems of science and education. Sep 2015. https://www.science-education.ru/ru/article/view?id=21800 (2018 Nov 16).
- Vural P, Kabaca G, Firat RD, et al. Administration of Selenium Decreases Lipid Peroxidation and Increases Vascular Endothelial Growth Factor in Streptozotocin Induced Diabetes Mellitus. Cell J. 2017; 19(3): 452–460.
- Mancia G, Fagard R, Narkiewicz K, et al. Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31(7): 1281–1357.
- Ministry of the Health of Ukraine. Order of the Ministry of Health of Ukraine dated 22 May.2009 № 356 "On approval of medical aid protocols for patients with endocrine diseases". 2009, May. http://www.moz.gov.ua/ua/portal/dn_20090805_574.html (2009, May 22).
- Ministry of the Health of Ukraine. Order of the Ministry of Health of Ukraine dated 21. Dec. 2012 № 1118 "On Approval and Implementation of Medical-Technological Documents for the Standardization of Medical Aid in Type 2 Diabetes". 2012, Dec . https://medprosvita.com.ua/nakaz-moz-ukrayini-vid-21-12-2012-n-1118-pro-zatver/ (2012, Dec. 21).
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38(1): 140–149.
- Pearce SHS, Brabant G, Duntas LH, et al. 2013 ETA Guideline: Management of Subclinical Hypothyroidism. Eur Thyroid J. 2013; 2(4): 215–228.
- McQuade C, Skugor M, Brennan DM, et al. Hypothyroidism and moderate subclinical hypothyroidism are associated with increased all-cause mortality independent of coronary heart disease risk factors: a PreCIS database study. Thyroid. 2011; 21(8): 837–843.
- Asvold BO, Vatten LJ, Nilsen TIL, et al. The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study. Eur J Endocrinol. 2007; 156(2): 181–186.
- Blankova ZN, Ageev FT, Seredenina EM et al [Hypothyroidism and cardio-vascular diseases]. Russian Med J. 2014(13): 980. https://www.rmj.ru/articles/endokrinologiya/gipotireoz-i-serdechno-sosudistye-zabolevaniya/#ixzz5X3TYvMkE (2018 Nov 16).
- Budnevskiy AV, Kravchenko AY, Feskova AA et al. [Dyslipidemia in subclinical hypofunction of the thyroid gland and the effectiveness of its correction by L-thyroxin replacement therapy]. Young Scientist 2014;17(76):138–142. https://moluch.ru/archive/76/12981/ (2018 Nov 16).
- Hamidi Shishavan M, Henning RH, van Buiten A, et al. Metformin Improves Endothelial Function and Reduces Blood Pressure in Diabetic Spontaneously Hypertensive Rats Independent from Glycemia Control: Comparison to Vildagliptin. Sci Rep. 2017; 7(1): 10975.
- Wu S, Li X, Zhang H. Effects of metformin on endothelial function in type 2 diabetes. Exp Ther Med. 2014; 7(5): 1349–1353.
- de Jager J, Kooy A, Schalkwijk C, et al. Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial. J Intern Med. 2014; 275(1): 59–70.